Skip to content

Clinical Efficacy of Essential-Oil Inhalation Therapy in Patients with Primary Insomnia

Clinical Efficacy of Essential-Oil Inhalation Therapy in Patients with Primary Insomnia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002381
Enrollment
Unknown
Registered
2025-12-06
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary insomnia

Interventions

Treatment group:Essential-Oil Inhalation Therapy
Control group:Routine bedtime health education

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18–80 years; sex unrestricted. (2) Primary complaint of insomnia meeting criteria 1)–7) for insomnia disorder in DSM-5. (3) Pittsburgh Sleep Quality Index (PSQI) global score > 7. (4) Corrected scores on both the Self-Rating Depression Scale and Self-Rating Anxiety Scale < 50. (5) If taking sleep-promoting medications, these must be limited to non-benzodiazepines, benzodiazepines, orexin-receptor antagonists, or melatonin-receptor agonists. (6) Willing to participate and has provided written informed consent.

Exclusion criteria

Exclusion criteria: (1) Failure to meet the above diagnostic or inclusion criteria. (2) Olfactory dysfunction or severe rhinitis. (3) Secondary insomnia, environmental sleep disorder, sleep-related breathing disorders (e.g., obstructive sleep apnea), or insomnia attributable to another psychiatric or medical condition. (4) Severe primary cardiac, hepatic, pulmonary, renal, or hematologic disease; any life-threatening illness; active psychiatric disorder; or significant suicide risk. (5) Current use of anxiolytic or antidepressant medications such as sertraline, deanxit, fluoxetine, escitalopram, paroxetine, or similar agents. (6) Alcohol or substance abuse/dependence within the past year. (7) Pregnant or lactating women. (8) Participation in another clinical drug trial within the 3 months prior to screening or currently enrolled in another trial. (9) Allergy history: hypersensitivity to plants in the Asteraceae (e.g., honeysuckle), Apiaceae (e.g., fennel), or Rutaceae (e.g., bergamot) families; or previous asthma attacks or severe rhinitis triggered by essential-oil inhalation. (10) Any other condition that, in the investigator's judgment, renders the patient unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index ;

Secondary

MeasureTime frame
The 7-item factors of the Pittsburgh Sleep Quality Index (PSQI);Insomnia Severity Index ;Self-rating Depression Scale;Self-rating Anxiety Scale;Polysomnography parameters;

Countries

China

Contacts

Public Contactqing ye

Longhua Hospital Shanghai University of Traditional Chinese Medicine

yeqing1982889@163.com13636304576

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026